Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment

BACKGROUND: The outcome of patients with acute myeloid leukemia (AML) aged ⩾65 years is poor. Effective treatment options are limited for patients with AML who cannot tolerate intensive chemotherapy. OBJECTIVES: We aimed to evaluate the efficacy of low-dose decitabine in previously untreated patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Ru, Zhang, Shuai, Li, Jiang-Tao, Wang, Ting, Zhang, Chun-Li, Bai, Jie-Fei, Yang, Lei, Wang, Li-Ru, Jing, Hong-Mei, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685783/
https://www.ncbi.nlm.nih.gov/pubmed/38033755
http://dx.doi.org/10.1177/20406207231208979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685783/
https://www.ncbi.nlm.nih.gov/pubmed/38033755
http://dx.doi.org/10.1177/20406207231208979

Ejemplares similares